EudraScore:改良Vigi4Eudra评分以评估EudraVigilance中药品不良反应报告完整性
德国联邦药品和医疗器械研究所专家小组基于共识改良Vigi4Eudra评分,调整惩罚项并新增因果关系相关类别,形成EudraScore。在用例中,EudraScore识别「至少可能」因果关联报告为「记录良好」的敏感度高于Vigi4Eudra评分(0.347 vs 0.245,p<0.001),特异度略低但差异无统计学意义。
要点
- EudraScore调整了缺失原产国和药物剂量的惩罚(10%降至5%),缺失自由文本描述惩罚增至30%。
- 新增患者病史、合并用药、再激发/去激发/措施、严重性作为加分项,并按惩罚分加权。
- EudraScore敏感度0.347(95%CI 0.293-0.405),高于Vigi4Eudra评分0.245(95%CI 0.197-0.299)。
核心结论
- EudraScore虽敏感度较低,但比Vigi4Eudra评分更适合对高相关性ADR报告进行优先排序。
- 进一步开发EudraScore以评估信息质量而非仅信息存在性可能带来显著价值。
研究设计与样本
- 由德国联邦药品和医疗器械研究所药物警戒与研究部门经验丰富的评估员组成专家小组。
- 基于专家共识改良Vigi4Eudra评分,调整惩罚项并新增因果关系相关类别,形成EudraScore。
- 通过用例比较EudraScore与Vigi4Eudra评分的计算值。
- 计算敏感度和特异度评估两种评分将「至少可能」因果关联报告识别为「记录良好」的性能。
主要发现
- 多数报告EudraScore值高于Vigi4Eudra评分,但差异普遍较小(≤0.1)。
- 差异主要来自药物剂量、严重性和患者病史类别。
- EudraScore敏感度0.347(95%CI 0.293-0.405),Vigi4Eudra评分0.245(95%CI 0.197-0.299),p<0.001。
- EudraScore特异度0.907(95%CI 0.860-0.940),Vigi4Eudra评分0.932(95%CI 0.889-0.959),p=0.07。
关键数值与推荐
- 缺失原产国和药物剂量的惩罚从10%降至5%。
- 当缺失发病时间和ADR结局信息时,缺失自由文本描述的惩罚从10%增至30%。
- 患者病史、合并用药、再激发/去激发/措施、严重性分别作为加分项(+10%、+10%、+10%、+5%)。
- 加分分按相应惩罚分加权。
临床怎么用
- EudraScore可用于药物警戒中对ADR报告进行优先排序,筛选出信息更完整、相关性更高的报告。
- 该评分有助于优化EudraVigilance报告的处理流程,但敏感度较低需结合其他评估。
局限性
- EudraScore的敏感度仍较低(0.347)。
- 完整性不直接反映因果关联强度。
- EudraScore仅评估信息存在性,未评估信息质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In the absence of a gold standard for assessing the completeness of spontaneous adverse drug reaction (ADR) reports, most studies have relied on assessing the proportion of reports containing information on predefined categories. The same principle applies to the Vigi4Eudra-score, which can be used to analyse the completeness of ADR reports from EudraVigilance. Moreover, ADR reports with a high level of information provided may be more useful in pharmacovigilance practice. The first aim of our study was to further develop the already existing Vigi4Eudra-score by modifying its penalties and by adding additional relevant categories (= EudraScore). The second aim was to assess whether the EudraScore performed better than the Vigi4Eudra-score to identify reports with at least a possible causal relationship as "well documented". METHODS: An expert panel was established comprising assessors from the pharmacovigilance and the research department of the German Federal Institute for Drugs and Medical Devices, with many years of experience in the assessment of ADR reports. Based on expert consensus, the Vigi4Eudra-score was modified by adapting existing categories and incorporating additional causality-relevant criteria, resulting in the EudraScore. A use case was conducted to compare the values calculated using the EudraScore with those obtained from the Vigi4Eudra-score. The performance of both scores in identifying reports with an "at least possible" causal relationship as "well documented" was evaluated by calculating sensitivity and specificity. RESULTS: Compared to the Vigi4Eudra-score, some penalties were adjusted for the EudraScore, with reduced penalties for missing country of origin and drug dose (from 10 to 5%) and an increased penalty for the absence of a free-text description (from 10 to 30%) when information on time to onset and ADR outcome is missing. The categories patient's history (+ 10%), concomitant drugs (+ 10%), rechallenge/dechallenge/action taken with the drug (+ 10%), and seriousness (+ 5%) were added as a bonus score. Finally, the bonus score was weighed by the respective penalty score. In the use case, most reports received higher values with the EudraScore compared to the Vigi4Eudra-score, although the differences were generally small (≤ 0.1). The categories drug dose, seriousness, and patient's history mostly led to the observed differences. Although the completeness does not directly reflect the strength of the causal association, the EudraScore received a higher sensitivity (0.347 [0.293-0.405]) compared to the Vigi4Eudra-score (0.245 [0.197-0.299], p < 0.001) and a negligibly lower specificity (EudraScore: 0.907 [0.860-0.940], Vigi4Eudra-score: 0.932 [0.889-0.959], p = 0.07) for identifying reports with an "at least possible" causal relationship as "well documented". CONCLUSION: Although the sensitivity was rather low, the EudraScore appears to be more suitable for the prioritisation of ADR reports of higher relevance than the Vigi4Eudra-score. Additionally, further development of the EudraScore to not only assess the presence of information but also information quality could add substantial value.
引用
- Dubrall D, Christ P, Lex D, et al. EudraScore: Modification of the Vigi4Eudra-score for the Assessment of the Completeness of Adverse Drug Reaction Reports in EudraVigilance. Drug Saf. 2026. PMID: 42905393. doi:10.1007/s40264-026-01720-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。